Encell, an advanced biopharmaceutical CDMO (Contract Development and Manufacturing Organization) and new drug development specialist, announced on the 27th that it has completed an additional CDMO production contract with Seoul Asan Medical Center for clinical research and advanced regenerative medicine clinical trials.
The key details of this contract are not disclosed due to a confidentiality agreement between the two parties. Since 2023, Encell has been supplying cells related to clinical research and advanced regenerative medicine to Seoul Asan Medical Center, and through this additional contract, it is believed that continuous and stable cell supply has become possible. Encell has demonstrated that it is a company capable of reliably supplying high-quality products that meet customer demands based on its unique raw cell manufacturing and supply capabilities through this additional contract.
Furthermore, following the amendment of the Advanced Regenerative Medicine Act effective from the 21st of last month, it is expected that the approval process for rare and intractable disease treatments using cell and gene therapies based on advanced regenerative medicine clinical research results will be expedited, thereby expanding opportunities for patient-tailored treatments.
An Encell representative stated, "Encell is collaborating with large medical institutions such as Seoul Asan Medical Center, which is developing various therapeutics including advanced regenerative medicine, not only producing cells but also providing consulting for advanced regenerative clinical research and treatments. We will accelerate additional collaborations with large medical institutions to proactively enter the rapidly growing advanced regenerative medicine market."
Meanwhile, since early this year, Encell has been providing consulting on advanced regenerative clinical research and treatments to major domestic medical institutions. Through this pre-marketing, Encell plans to continuously expand its connections with medical institutions to create a favorable environment as a leading CDMO in cell and gene therapies and to sufficiently offer treatment options desired by medical institutions and patients in the future.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
